190 related articles for article (PubMed ID: 18636958)
1. No impairment of endothelial function or insulin sensitivity with 4 weeks of the HIV protease inhibitors atazanavir or lopinavir-ritonavir in healthy subjects without HIV infection: a placebo-controlled trial.
Dubé MP; Shen C; Greenwald M; Mather KJ
Clin Infect Dis; 2008 Aug; 47(4):567-74. PubMed ID: 18636958
[TBL] [Abstract][Full Text] [Related]
2. Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically.
Noor MA; Flint OP; Maa JF; Parker RA
AIDS; 2006 Sep; 20(14):1813-21. PubMed ID: 16954722
[TBL] [Abstract][Full Text] [Related]
3. GS-8374, a novel HIV protease inhibitor, does not alter glucose homeostasis in cultured adipocytes or in a healthy-rodent model system.
Hruz PW; Yan Q; Tsai L; Koster J; Xu L; Cihlar T; Callebaut C
Antimicrob Agents Chemother; 2011 Apr; 55(4):1377-82. PubMed ID: 21245443
[TBL] [Abstract][Full Text] [Related]
4. The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults.
Noor MA; Parker RA; O'Mara E; Grasela DM; Currie A; Hodder SL; Fiedorek FT; Haas DW
AIDS; 2004 Nov; 18(16):2137-44. PubMed ID: 15577646
[TBL] [Abstract][Full Text] [Related]
5. The protease inhibitor combination lopinavir/ritonavir does not decrease insulin secretion in healthy, HIV-seronegative volunteers.
Pao VY; Lee GA; Taylor S; Aweeka FT; Schwarz JM; Mulligan K; Schambelan M; Grunfeld C
AIDS; 2010 Jan; 24(2):265-70. PubMed ID: 19890203
[TBL] [Abstract][Full Text] [Related]
6. Insulin sensitivity is preserved despite disrupted endothelial function.
Shankar SS; Considine RV; Gorski JC; Steinberg HO
Am J Physiol Endocrinol Metab; 2006 Oct; 291(4):E691-6. PubMed ID: 16705064
[TBL] [Abstract][Full Text] [Related]
7. Improvement in insulin sensitivity and dyslipidemia in protease inhibitor-treated adult male patients after switch to atazanavir/ritonavir.
Busti AJ; Bedimo R; Margolis DM; Hardin DS
J Investig Med; 2008 Feb; 56(2):539-44. PubMed ID: 18317438
[TBL] [Abstract][Full Text] [Related]
8. Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial.
Cohen C; Nieto-Cisneros L; Zala C; Fessel WJ; Gonzalez-Garcia J; Gladysz A; McGovern R; Adler E; McLaren C;
Curr Med Res Opin; 2005 Oct; 21(10):1683-92. PubMed ID: 16238909
[TBL] [Abstract][Full Text] [Related]
9. The metabolic effects of lopinavir/ritonavir in HIV-negative men.
Lee GA; Seneviratne T; Noor MA; Lo JC; Schwarz JM; Aweeka FT; Mulligan K; Schambelan M; Grunfeld C
AIDS; 2004 Mar; 18(4):641-9. PubMed ID: 15090769
[TBL] [Abstract][Full Text] [Related]
10. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.
Molina JM; Andrade-Villanueva J; Echevarria J; Chetchotisakd P; Corral J; David N; Moyle G; Mancini M; Percival L; Yang R; Thiry A; McGrath D;
Lancet; 2008 Aug; 372(9639):646-55. PubMed ID: 18722869
[TBL] [Abstract][Full Text] [Related]
11. Effects of switching from lopinavir/ritonavir to atazanavir/ritonavir on muscle glucose uptake and visceral fat in HIV-infected patients.
Stanley TL; Joy T; Hadigan CM; Liebau JG; Makimura H; Chen CY; Thomas BJ; Weise SB; Robbins GK; Grinspoon SK
AIDS; 2009 Jul; 23(11):1349-57. PubMed ID: 19474651
[TBL] [Abstract][Full Text] [Related]
12. Severe impairment of endothelial function with the HIV-1 protease inhibitor indinavir is not mediated by insulin resistance in healthy subjects.
Dubé MP; Gorski JC; Shen C
Cardiovasc Toxicol; 2008 Mar; 8(1):15-22. PubMed ID: 18172783
[TBL] [Abstract][Full Text] [Related]
13. Direct comparison of the acute in vivo effects of HIV protease inhibitors on peripheral glucose disposal.
Yan Q; Hruz PW
J Acquir Immune Defic Syndr; 2005 Dec; 40(4):398-403. PubMed ID: 16280693
[TBL] [Abstract][Full Text] [Related]
14. Two cases of multidrug-resistant human immunodeficiency virus infection treated with atazanavir and lopinavir/ritonavir combination therapy.
Choi H; Jeong SJ; Lee HS; Chin BS; Choi SH; Han SH; Kim MS; Kim CO; Choi JY; Song YG; Kim JM
J Korean Med Sci; 2008 Aug; 23(4):737-9. PubMed ID: 18756069
[TBL] [Abstract][Full Text] [Related]
15. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study.
Molina JM; Andrade-Villanueva J; Echevarria J; Chetchotisakd P; Corral J; David N; Moyle G; Mancini M; Percival L; Yang R; Wirtz V; Lataillade M; Absalon J; McGrath D;
J Acquir Immune Defic Syndr; 2010 Mar; 53(3):323-32. PubMed ID: 20032785
[TBL] [Abstract][Full Text] [Related]
16. Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure.
Di Giambenedetto S; De Luca A; Villani P; Bacarelli A; Ragazzoni E; Regazzi M; Cauda R; Navarra P
HIV Med; 2008 Apr; 9(4):239-45. PubMed ID: 18366448
[TBL] [Abstract][Full Text] [Related]
17. Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study.
Squires KE; Johnson M; Yang R; Uy J; Sheppard L; Absalon J; McGrath D
J Antimicrob Chemother; 2011 Feb; 66(2):363-70. PubMed ID: 21148235
[TBL] [Abstract][Full Text] [Related]
18. HIV protease inhibitors induce metabolic dysfunction in part via increased JNK1/2 pro-inflammatory signaling in L6 cells.
Bogachus LD; Turcotte LP
Antiviral Res; 2011 Dec; 92(3):415-23. PubMed ID: 21968131
[TBL] [Abstract][Full Text] [Related]
19. Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.
Waters LJ; Moyle G; Bonora S; D'Avolio A; Else L; Mandalia S; Pozniak A; Nelson M; Gazzard B; Back D; Boffito M
Antivir Ther; 2007; 12(5):825-30. PubMed ID: 17713166
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.
Soriano V; García-Gasco P; Vispo E; Ruiz-Sancho A; Blanco F; Martín-Carbonero L; Rodríguez-Novoa S; Morello J; de Mendoza C; Rivas P; Barreiro P; González-Lahoz J
J Antimicrob Chemother; 2008 Jan; 61(1):200-5. PubMed ID: 17999977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
